- Recce Pharmaceuticals (RCE) announces positive data from its phase one intravenous clinical trial for RECCE 327 (R327)
- R327 is designed to treat serious bacterial infections including sepsis
- In its first cohort of the phase one trial, nine healthy male subjects demonstrated R327’s safety and tolerability
- An independent safety committee has now approved an increase in dosage from 50 milligrams to 150 milligrams in the second cohort
- The study is on track to have all Phase I dosing complete by the second quarter of this year
- Shares are trading 6.80 per cent higher today at $1.10 each
Recce Pharmaceuticals (RCE) has announced positive data from its phase one intravenous clinical trial for RECCE 327 (R327).
R327 is designed to treat serious bacterial infections including sepsis.
In its first cohort of the phase one trial, nine healthy male subjects demonstrated R327’s safety and tolerability. There were no clinically significant changes in vital signs, clinical, adverse events, or laboratory parameters associated with R327.
An independent safety committee has now approved an increase in dosage from 50 milligrams to 150 milligrams in the second cohort, with subjects expected to be dosed today at Adelaide’s CMAX clinical trial facility.
CEO James Graham said he is pleased with the results.
“R327 continues to make significant progress in the clinic, both in this Phase I intravenous trial and a parallel Phase I/II topical trial on patients with serious burn wound infections,” he said.
“We’re pleased to see R327 (50mg) tolerated as an intravenous infusion in Cohort One subjects.”
The study is on track to have all phase one dosing complete by the second quarter of this year.
Shares are trading 6.80 per cent higher today at $1.10 each at 11.24 pm AEDT.